Gene therapy medicinal products May 2020 | By Martin Bradley Gene therapy medicinal products (GTMPs) are advanced therapy medicinal products (ATMPs): medicines for human use that are based on genes, tissues, or cells. They offer […]
Generic HIV treatments permit cost savings, but their implementation can be complex February 2020 | By Martin Bradley National spending on specialised services for the treatment of HIV is significant; in 2016/17, it was close to £540 million, of which antiretroviral treatment (ART) […]
The new Commissioning for Quality and Innovation indicator on antifungal stewardship November 2019 | By Martin Bradley Antimicrobial stewardship is a healthcare system-wide approach to promoting and monitoring the judicious use of antimicrobials, such as antifungals, to preserve their future effectiveness.1 Such […]
Mexiletine: now licensed for myotonia, but what about arrhythmia? September 2019 | By Martin Bradley Mexiletine is a sodium channel blocker, and was originally developed as an anticonvulsant drug.1,2 However, it was found to have anti-arrhythmic properties, and has been […]
IVIg: new commissioning criteria and sub-regional panels May 2019 | By Martin Bradley As this journal has previously highlighted, continuity of intravenous immunoglobulin (IVIg) supply is a long-standing issue for the NHS. There have been several significant supply […]
New legislation for cannabis-based products for medicinal use February 2019 | By Martin Bradley Martin Bradley outlines provisional guidance on when medical cannabis can be prescribed, ahead of a forthcoming NICE guideline
